spaq-co disp dispersible tablets 250/12.5/76.5
shanghai fosun pharmaceutical industrial development co., ltd, china - sulfadoxine/pyrimethamine/amodiaquine (as hydrochloride) - dispersible tablets - 250/12.5/76.5
spaq-co disp dispersible tablets
shanghai fosun pharmaceutical industrial development co., ltd, china - sulfadoxine/pyrimethamine/amodiaquine (as hydrochloride) - dispersible tablets - 500/25
spaq-co® disp 500mg/25mg/153mg dispersible tablet
shanghai fosun pharmaceutical industrial room 350, no. 25 kangshi road, kangqiao town, - sulfadoxine/ pyrimethamine/ amodiaquine - dispersible tablet - sulfadoxine 500mg/ pyrimethamine 25mg/ - amodiaquine
spaq-co dispersible tablets 250/12.5/76.5
shanghai fosun pharmaceutical development co., ltd, china - sulfadoxine/pyrimethamine/amodiaquine (as hydrochloride) - dispersible tablets - 250/12.5/76.5
wimal plus hs dispersible tablets 500/150/25
universal corporation limited, kenya - sulfadoxine/pyrimethamine/amodiaquine (as hydrochloride) - dispersible tablets - 500/150/25
wimal plus hs dispersible tablets 250/12.5 mg and 75 mg
universal corporation limited, kenya - sulfadoxine/pyrimethamine/amodiaquine (as hydrochloride) - dispersible tablets - 250/12.5 mg and 75 mg
wimal plus adult dispersible tablet
universal corporation limited club road, plot no. 13777, p.o box 1748 - 00902, - sulfadoxine, pyrimethamine and amodiaquine - dispersible tablet - each tablet of sulfadoxine/pyrimethamine contains - amodiaquine
wimal plus junior dispersible tablet
universal corporation limited club road, plot no. 13777, p.o box 1748 - 00902, - sulfadoxine, pyrimethamine and amodiaquine - dispersible tablet - each tablet of sulfadoxine/pyrimethamine contains - amodiaquine
spaq-co® disp 250mg/12.5mg /76.5mg dispersible tablet
shanghai fosun pharmaceutical industrial room 350, no. 25 kangshi road, kangqiao town, - sulfadoxine, pyrimethamine, amodiaquine - dispersible tablet - 250 mg sulfadoxine , 12.5 mg pyrimethamine and - pyrimethamine combinations
mefloquine hydrochloride- mefloquine hydrochloride tablet
west-ward pharmaceuticals corp - mefloquine hydrochloride (unii: 5y9l3636o3) (mefloquine - unii:tml814419r) - mefloquine hydrochloride 250 mg - treatment of acute malaria infections : mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of p. falciparum (both chloroquine-susceptible and resistant strains) or by plasmodium vivax. there are insufficient clinical data to document the effect of mefloquine in malaria caused by p. ovale or p. malariae. note: patients with acute p. vivax malaria, treated with mefloquine, are at high risk of relapse because mefloquine does not eliminate exoerythrocytic (hepatic phase) parasites. to avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). prevention of malaria : mefloquine hydrochloride tablets are indicated for the prophylaxis of p. falciparum and p. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of p. falciparum. use of mefloquine hydrochloride tablets is contraindica